C09980410 / invoice 10000
Species:CANINE
Breed:American Staffordshire Terrier Cross
Age (years):11
Diagnosis or signs:Urothelial Carcinoma
Consult notes
Chemotherapy WEEK 14 – MITOXANTRONEAppointment Notes: Week 14 History:E/D ok. No constipation, good energy. Urinating ok. Continues to leave blood spots around the house but no more than previously. Good energy. Main concern is Hyper A signs returning (shaking, not especially PU/PD – wasn’t last time either). Sporadic – nil hair regrowth as expected. Now on mitoxantrone only q3wk, no further vinblastine.Current Medication: - Gabapentin PO BID - Panadol PO BID - Firocoxib 227mg PO SID Examination: - Weight change = -100 g - L ing LN = 29 mm - R ing LN/mass = 45 mm - Subjectively surrounding tissue is softer / less inflammatory than last time; Lnn more discrete? Laboratory: - CHEM - ALT 191 (alkp 118, tbil 7) - CBC – WNL (NEU 12.4, PLT 355) - Blood smear – adequate platelets, no morphological abnormalities seen Chemotherapy: - Drug = Mitoxantrone - Dose = 5 mg/m2 - Route = IV - Details = Right accessory cephalic. 10 ml saline pre-flush, 1.7ml mitoxantrone over 5 mins, 20 ml saline post-flush. - No evidence ADR or extravasation - 0.05 ml medetomidine IV to help keep calm in hospital until picked up. Plan:Revisit in 3 weeks for next mitoxantrone.
Animal clinical history (3 most recent)
2026-03-03T00:00:00Z 8:26?am
Chemotherapy WEEK 14 – MITOXANTRONEAppointment Notes: Week 14 History:E/D ok. No constipation, good energy. Urinating ok. Continues to leave blood spots around the house but no more than previously. Good energy. Main concern is Hyper A signs returning (shaking, not especially PU/PD – wasn’t last time either). Sporadic – nil hair regrowth as expected. Now on mitoxantrone only q3wk, no further vinblastine.Current Medication: - Gabapentin PO BID - Panadol PO BID - Firocoxib 227mg PO SID Examination: - Weight change = -100 g - L ing LN = 29 mm - R ing LN/mass = 45 mm - Subjectively surrounding tissue is softer / less inflammatory than last time; Lnn more discrete? Laboratory: - CHEM - ALT 191 (alkp 118, tbil 7) - CBC – WNL (NEU 12.4, PLT 355) - Blood smear – adequate platelets, no morphological abnormalities seen Chemotherapy: - Drug = Mitoxantrone - Dose = 5 mg/m2 - Route = IV - Details = Right accessory cephalic. 10 ml saline pre-flush, 1.7ml mitoxantrone over 5 mins, 20 ml saline post-flush. - No evidence ADR or extravasation - 0.05 ml medetomidine IV to help keep calm in hospital until picked up. Plan:Revisit in 3 weeks for next mitoxantrone. Vital Signs Weight: 18;
Previous claim history (11)
| Date | Claim # | Diagnosis |
|---|---|---|
| 2026-02-09 | C09882963 | CARCINOMA/CARCINOMA IN SITU |
| 2026-01-20 | C09785926 | CARCINOMA/CARCINOMA IN SITU - URETHRAL |
| 2026-01-19 | C09778121 | CARCINOMA/CARCINOMA IN SITU - URETHRAL |
| 2026-01-13 | C09775432 | OSTEOARTHRITIS |
| 2026-01-12 | C09743412 | CARCINOMA/CARCINOMA IN SITU - URETHRAL |
| 2026-01-12 | C09743936 | CARCINOMA/CARCINOMA IN SITU - URETHRAL |
| 2016-10-10 | C0959760 | OTITIS MEDIA |
| 2016-09-19 | C0930039 | EAR INFECTION |
| 2016-09-19 | C0930039 | VACCINATIONS OR HEALTH CHECKS |
| 2016-09-02 | C0922130 | EAR INFECTION |
| 2016-06-27 | C0871740 | CONJUNCTIVITIS |
Line items(lines with upstream diagnosis are skipped by the model)
| Line | tstarc | Amount | Date | Upstream diagnosis |
|---|---|---|---|---|
| 10000 | tstarc_diagnostic_test_-_biochemistry | 23.09 | 2026-03-03 | — |
| 20000 | tstarc_diagnostic_test_-_biochemistry | 23.10 | 2026-03-03 | — |
| 30000 | tstarc_diagnostic_test_-_haematology | 47.30 | 2026-03-03 | — |
| 40000 | tstarc_hospitalisation | 100.00 | 2026-03-03 | — |
| 50000 | tstarc_iv_catheterisation | 49.80 | 2026-03-03 | — |
| 60000 | tstarc_procedure_fee_-_blood_collection | 36.80 | 2026-03-03 | — |
| 70000 | tstarc_diagnostic_test_-_bile_acid | 23.10 | 2026-03-03 | — |
| 80000 | tstarc_chemotherapy | 253.96 | 2026-03-03 | — |
| 90000 | tstarc_chemotherapy | 58.30 | 2026-03-03 | — |
| 100000 | tstarc_sedation_for_procedure | 44.00 | 2026-03-03 | — |
| 110000 | tstarc_disposables | 32.30 | 2026-03-03 | — |
UPM+
- DG00366CARCINOMA/CARCINOMA IN SITU - URETHRALDSTP_carcinoma
Variant (sleepy_king)
CARCINOMA/CARCINOMA IN SITU
DSTP_carcinoma
Conf: 0.990
Threshold: 0.33
Above: ✓
Correct?